
8. Literaturverzeichnis

1. **Alyautdin, R. N., V. E. Petrov, K. Langer, A. Berthold, D. A. Kharkevich, and J. Kreuter.** 1997. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. *Pharm Res* **14**:325-8.
2. **Andras, I. E., H. Pu, M. A. Deli, A. Nath, B. Hennig, and M. Toborek.** 2003. HIV-1 Tat protein alters tight junction protein expression and distribution in cultured brain endothelial cells. *J Neurosci Res* **74**:255-65.
3. **Araujo, F. G., C. A. Hunter, and J. S. Remington.** 1997. Treatment with interleukin 12 in combination with atovaquone or clindamycin significantly increases survival of mice with acute toxoplasmosis. *Antimicrob Agents Chemother* **41**:188-90.
4. **Araujo, F. G., J. Huskinson, and J. S. Remington.** 1991. Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of *Toxoplasma gondii*. *Antimicrob Agents Chemother* **35**:293-9.
5. **Araujo, F. G., T. Lin, and J. S. Remington.** 1993. The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine. *J Infect Dis* **167**:494-7.
6. **Araujo, F. G., T. Slifer, and J. S. Remington.** 1994. Rifabutin is active in murine models of toxoplasmosis. *Antimicrob Agents Chemother* **38**:570-5.
7. **Audus, K. L., and R. T. Borchardt.** 1987. Bovine brain microvessel endothelial cell monolayers as a model system for the blood-brain barrier. *Ann N Y Acad Sci* **507**:9-18.
8. **Baggish, A. L., and D. R. Hill.** 2002. Antiparasitic agent atovaquone. *Antimicrob Agents Chemother* **46**:1163-73.
9. **Barragan, A., F. Brossier, and L. D. Sibley.** 2005. Transepithelial migration of *Toxoplasma gondii* involves an interaction of intercellular adhesion molecule 1 (ICAM-1) with the parasite adhesin MIC2. *Cell Microbiol* **7**:561-8.
10. **Bauer, H., U. Sonnleitner, A. Lametschwandtner, M. Steiner, H. Adam, and H. C. Bauer.** 1995. Ontogenic expression of the erythroid-type glucose transporter (Glut 1) in the telencephalon of the mouse: correlation to the tightening of the blood-brain barrier. *Brain Res Dev Brain Res* **86**:317-25.
11. **Bauer, H., W. Stelzhammer, R. Fuchs, T. M. Weiger, C. Danninger, G. Probst, and I. A. Krizbai.** 1999. Astrocytes and neurons express the tight junction-specific protein occludin in vitro. *Exp Cell Res* **250**:434-8.
12. **Betz, A. L., and G. W. Goldstein.** 1980. The basis for active transport at the blood-brain barrier. *Adv Exp Med Biol* **131**:5-16.
13. **Bickel, U., Y. S. Kang, T. Yoshikawa, and W. M. Pardridge.** 1994. In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium. *J Histochem Cytochem* **42**:1493-7.
14. **Biegel, D., D. D. Spencer, and J. S. Pachter.** 1995. Isolation and culture of human brain microvessel endothelial cells for the study of blood-brain barrier properties in vitro. *Brain Res* **692**:183-9.

-
15. **Blasig, I. E., H. Giese, M. L. Schroeter, A. Sporberr, D. I. Utepbergenov, I. B. Buchwalow, K. Neubert, G. Schonfelder, D. Freyer, I. Schimke, W. E. Siems, M. Paul, R. F. Haseloff, and R. Blasig.** 2001. *NO and oxyradical metabolism in new cell lines of rat brain capillary endothelial cells forming the blood-brain barrier. *Microvasc Res* **62**:114-27.
 16. **Blasig, I. E., K. Mertsch, and R. F. Haseloff.** 2002. Nitronyl nitroxides, a novel group of protective agents against oxidative stress in endothelial cells forming the blood-brain barrier. *Neuropharmacology* **43**:1006-14.
 17. **Borchard, G., and J. Kreuter.** 1993. Interaction of serum components with poly(methylmethacrylate) nanoparticles and the resulting body distribution after intravenous injection in rats. *J Drug Target* **1**:15-9.
 18. **Bowman, P. D., A. L. Betz, D. Ar, J. S. Wolinsky, J. B. Penney, R. R. Shivers, and G. W. Goldstein.** 1981. Primary culture of capillary endothelium from rat brain. *In Vitro* **17**:353-62.
 19. **Chamoux, M., M. P. Dehouck, J. C. Fruchart, G. Spik, J. Montreuil, and R. Cecchelli.** 1991. Characterization of angiogenin receptors on bovine brain capillary endothelial cells. *Biochem Biophys Res Commun* **176**:833-9.
 20. **Dannemann, B. R., D. M. Israelski, G. S. Leoung, T. McGraw, J. Mills, and J. S. Remington.** 1991. Toxoplasma serology, parasitemia and antigenemia in patients at risk for toxoplasmic encephalitis. *Aids* **5**:1363-5.
 21. **Daubener, W., B. Spors, C. Hucke, R. Adam, M. Stins, K. S. Kim, and H. Schrotten.** 2001. Restriction of *Toxoplasma gondii* growth in human brain microvascular endothelial cells by activation of indoleamine 2,3-dioxygenase. *Infect Immun* **69**:6527-31.
 22. **Dehouck, M. P., P. Jolliet-Riant, F. Bree, J. C. Fruchart, R. Cecchelli, and J. P. Tillement.** 1992. Drug transfer across the blood-brain barrier: correlation between in vitro and in vivo models. *J Neurochem* **58**:1790-7.
 23. **Deli, M. A., Abraham, C.S; Kataoka, Y.; Niwa M.** 2005. Permeability studies on in vitro blood-brain barrier models: physiology, pathology and pharmacology. *Cell. Mol. Neurobiol* **25**: 59-127, 2005.
 24. **Deli, M. A., and F. Joo.** 1996. Cultured vascular endothelial cells of the brain. *Keio J Med* **45**:183-98; discussion 198-9.
 25. **Deli, M. A., S. Sakaguchi, R. Nakaoka, C. S. Abraham, H. Takahata, J. Kopacek, K. Shigematsu, S. Katamine, and M. Niwa.** 2000. PrP fragment 106-126 is toxic to cerebral endothelial cells expressing PrP(C). *Neuroreport* **11**:3931-6.
 26. **Dermietzel, R., E. L. Hertberg, J. A. Kessler, and D. C. Spray.** 1991. Gap junctions between cultured astrocytes: immunocytochemical, molecular, and electrophysiological analysis. *J Neurosci* **11**:1421-32.
 27. **dHuskinson-Mark, J., F. G. Araujo, and J. S. Remington.** 1991. Evaluation of the effect of drugs on the cyst form of *Toxoplasma gondii*. *J Infect Dis* **164**:170-1.
 28. **Dixon, R., A. L. Pozniak, H. M. Watt, P. Rolan, and J. Posner.** 1996. Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients. *Antimicrob Agents Chemother* **40**:556-60.
 29. **Djurkovic-Djakovic, O., V. Milenkovic, A. Nikolic, B. Bobic, and J. Grujic.** 2002. Efficacy of atovaquone combined with clindamycin against murine infection

-
- with a cystogenic (Me49) strain of *Toxoplasma gondii*. *J Antimicrob Chemother* **50**:981-7.
30. **Dunay, I. R., M. M. Heimesaat, F. N. Bushrab, R. H. Muller, H. Stocker, K. Arasteh, M. Kurowski, R. Fitzner, K. Borner, and O. Liesenfeld.** 2004. Atovaquone maintenance therapy prevents reactivation of toxoplasmic encephalitis in a murine model of reactivated toxoplasmosis. *Antimicrob Agents Chemother* **48**:4848-54.
 31. **Duport, S., F. Robert, D. Muller, G. Grau, L. Parisi, and L. Stoppini.** 1998. An in vitro blood-brain barrier model: cocultures between endothelial cells and organotypic brain slice cultures. *Proc Natl Acad Sci U S A* **95**:1840-5.
 32. **Eisenblatter, T., S. Huwel, and H. J. Galla.** 2003. Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood-brain barrier. *Brain Res* **971**:221-31.
 33. **el Hafny, B., J. M. Bourre, and F. Roux.** 1996. Synergistic stimulation of gamma-glutamyl transpeptidase and alkaline phosphatase activities by retinoic acid and astroglial factors in immortalized rat brain microvessel endothelial cells. *J Cell Physiol* **167**:451-60.
 34. **Farquhar, J. D.** 1963. Iron Supplementation During First Year of Life. *Am J Dis Child* **106**:201-6.
 35. **Fenart, L., A. Casanova, B. Dehouck, C. Duhem, S. Slupek, R. Cecchelli, and D. Betbeder.** 1999. Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier. *J Pharmacol Exp Ther* **291**:1017-22.
 36. **Ferguson, D. J., J. Huskinson-Mark, F. G. Araujo, and J. S. Remington.** 1994. A morphological study of chronic cerebral toxoplasmosis in mice: comparison of four different strains of *Toxoplasma gondii*. *Parasitol Res* **80**:493-501.
 37. **Frenkel, J. K., B. M. Nelson, and J. Arias-Stella.** 1975. Immunosuppression and toxoplasmic encephalitis: clinical and experimental aspects. *Hum Pathol* **6**:97-111.
 38. **Furuse, M., K. Fujita, T. Hiragi, K. Fujimoto, and S. Tsukita.** 1998. Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. *J Cell Biol* **141**:1539-50.
 39. **Furuse, M., T. Hirase, M. Itoh, A. Nagafuchi, S. Yonemura, and S. Tsukita.** 1993. Occludin: a novel integral membrane protein localizing at tight junctions. *J Cell Biol* **123**:1777-88.
 40. **Gazzinelli, R., Y. Xu, S. Hieny, A. Cheever, and A. Sher.** 1992. Simultaneous depletion of CD4+ and CD8+ T lymphocytes is required to reactivate chronic infection with *Toxoplasma gondii*. *J Immunol* **149**:175-80.
 41. **Gazzinelli, R. T., S. Hieny, T. A. Wynn, S. Wolf, and A. Sher.** 1993. Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts. *Proc Natl Acad Sci U S A* **90**:6115-9.
 42. **Gazzinelli, R. T., M. Wysocka, S. Hayashi, E. Y. Denkers, S. Hieny, P. Caspar, G. Trinchieri, and A. Sher.** 1994. Parasite-induced IL-12 stimulates early IFN-gamma synthesis and resistance during acute infection with *Toxoplasma gondii*. *J Immunol* **153**:2533-43.

-
43. **Gloor, S. M., M. Wachtel, M. F. Bolliger, H. Ishihara, R. Landmann, and K. Frei.** 2001. Molecular and cellular permeability control at the blood-brain barrier. *Brain Res Brain Res Rev* **36**:258-64.
 44. **Grab, D. J., G. Perides, J. S. Dumler, K. J. Kim, J. Park, Y. V. Kim, O. Nikolskaia, K. S. Choi, M. F. Stins, and K. S. Kim.** 2005. *Borrelia burgdorferi*, host-derived proteases, and the blood-brain barrier. *Infect Immun* **73**:1014-22.
 45. **Grau, M. J., O. Kayser, and R. H. Muller.** 2000. Nanosuspensions of poorly soluble drugs--reproducibility of small scale production. *Int J Pharm* **196**:155-9.
 46. **Greenwood, J., G. Pryce, L. Devine, D. K. Male, W. L. dos Santos, V. L. Calder, and P. Adamson.** 1996. SV40 large T immortalised cell lines of the rat blood-brain and blood-retinal barriers retain their phenotypic and immunological characteristics. *J Neuroimmunol* **71**:51-63.
 47. **Gumbleton, M., and K. L. Audus.** 2001. Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier. *J Pharm Sci* **90**:1681-98.
 48. **Hirase, T., J. M. Staddon, M. Saitou, Y. Ando-Akatsuka, M. Itoh, M. Furuse, K. Fujimoto, S. Tsukita, and L. L. Rubin.** 1997. Occludin as a possible determinant of tight junction permeability in endothelial cells. *J Cell Sci* **110 (Pt 14)**:1603-13.
 49. **Hogh, B., P. D. Clarke, D. Camus, H. D. Nothdurft, D. Overbosch, M. Gunther, I. Joubert, K. C. Kain, D. Shaw, N. S. Roskell, and J. D. Chulay.** 2000. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone International Study Team. *Lancet* **356**:1888-94.
 50. **Holtshcke, T., J. Lohler, Y. Kanno, T. Fehr, N. Giese, F. Rosenbauer, J. Lou, K. P. Knobloch, L. Gabriele, J. F. Waring, M. F. Bachmann, R. M. Zinkernagel, H. C. Morse, 3rd, K. Ozato, and I. Horak.** 1996. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. *Cell* **87**:307-17.
 51. **Huai-Yun, H., D. T. Secrest, K. S. Mark, D. Carney, C. Brandquist, W. F. Elmquist, and D. W. Miller.** 1998. Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells. *Biochem Biophys Res Commun* **243**:816-20.
 52. **Huber, J. D., R. D. Egleton, and T. P. Davis.** 2001. Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. *Trends Neurosci* **24**:719-25.
 53. **Hughes, W. T., W. Kennedy, J. L. Shenep, P. M. Flynn, S. V. Hetherington, G. Fullen, D. J. Lancaster, D. S. Stein, S. Palte, D. Rosenbaum, and et al.** 1991. Safety and pharmacokinetics of 566C80, a hydroxynaphthoquinone with anti-*Pneumocystis carinii* activity: a phase I study in human immunodeficiency virus (HIV)-infected men. *J Infect Dis* **163**:843-8.
 54. **Hurst, R. D., and I. B. Fritz.** 1996. Properties of an immortalised vascular endothelial/glioma cell co-culture model of the blood-brain barrier. *J Cell Physiol* **167**:81-8.
 55. **Huwylar, J., J. Drewe, C. Klusemann, and G. Fricker.** 1996. Evidence for P-glycoprotein-modulated penetration of morphine-6-glucuronide into brain capillary endothelium. *Br J Pharmacol* **118**:1879-85.

-
56. **Israelski, D. M., and J. S. Remington.** 1993. Toxoplasmosis in patients with cancer. *Clin Infect Dis* **17 Suppl 2**:S423-35.
 57. **Israelski, D. M., and J. S. Remington.** 1993. Toxoplasmosis in the non-AIDS immunocompromised host. *Curr Clin Top Infect Dis* **13**:322-56.
 58. **Itoh, M., M. Furuse, K. Morita, K. Kubota, M. Saitou, and S. Tsukita.** 1999. Direct binding of three tight junction-associated MAGUKs, ZO-1, ZO-2, and ZO-3, with the COOH termini of claudins. *J Cell Biol* **147**:1351-63.
 59. **Jesaitis, L. A., and D. A. Goodenough.** 1994. Molecular characterization and tissue distribution of ZO-2, a tight junction protein homologous to ZO-1 and the *Drosophila* discs-large tumor suppressor protein. *J Cell Biol* **124**:949-61.
 60. **Joo, F.** 1992. The cerebral microvessels in culture, an update. *J Neurochem* **58**:1-17.
 61. **Juliano, R. L.** 1976. The role of drug delivery systems in cancer chemotherapy. *Prog Clin Biol Res* **9**:21-32.
 62. **Katlama, C., S. De Wit, E. O'Doherty, M. Van Glabeke, and N. Clumeck.** 1996. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. *Clin Infect Dis* **22**:268-75.
 63. **Katlama, C., B. Mouthon, D. Gourdon, D. Lapierre, and F. Rousseau.** 1996. Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. Atovaquone Expanded Access Group. *Aids* **10**:1107-12.
 64. **Khan, A. A., F. G. Araujo, J. C. Craft, and J. S. Remington.** 2000. Ketolide ABT-773 is active against *Toxoplasma gondii*. *J Antimicrob Chemother* **46**:489-92.
 65. **Khan, A. A., T. Slifer, F. G. Araujo, R. J. Polzer, and J. S. Remington.** 1997. Activity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosis. *Antimicrob Agents Chemother* **41**:893-7.
 66. **Kim, D. H., H. Iijima, K. Goto, J. Sakai, H. Ishii, H. J. Kim, H. Suzuki, H. Kondo, S. Saeki, and T. Yamamoto.** 1996. Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain. *J Biol Chem* **271**:8373-80.
 67. **Krause, D., U. Mischeck, H. J. Galla, and R. Dermietzel.** 1991. Correlation of zonula occludens ZO-1 antigen expression and transendothelial resistance in porcine and rat cultured cerebral endothelial cells. *Neurosci Lett* **128**:301-4.
 68. **Kreuter, J., R. N. Alyautdin, D. A. Kharkevich, and A. A. Ivanov.** 1995. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). *Brain Res* **674**:171-4.
 69. **Kreuter, J., D. Shamenkov, V. Petrov, P. Ramge, K. Cychutek, C. Koch-Brandt, and R. Alyautdin.** 2002. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. *J Drug Target* **10**:317-25.
 70. **Lasbennes, F., and J. Gayet.** 1984. Capacity for energy metabolism in microvessels isolated from rat brain. *Neurochem Res* **9**:1-10.
 71. **Lechardeur, D., B. Schwartz, D. Paulin, and D. Scherman.** 1995. Induction of blood-brain barrier differentiation in a rat brain-derived endothelial cell line. *Exp Cell Res* **220**:161-70.

-
72. **Liesenfeld, O., I. R. Dunay, and K. J. Erb.** 2004. Infection with *Toxoplasma gondii* reduces established and developing Th2 responses induced by *Nippostrongylus brasiliensis* infection. *Infect Immun* **72**:3812-22.
 73. **Luft, B. J., and J. S. Remington.** 1988. AIDS commentary. Toxoplasmic encephalitis. *J Infect Dis* **157**:1-6.
 74. **Luft, B. J., and J. S. Remington.** 1992. Toxoplasmic encephalitis in AIDS. *Clin Infect Dis* **15**:211-22.
 75. **Mantych, G. J., G. S. Hageman, and S. U. Devaskar.** 1993. Characterization of glucose transporter isoforms in the adult and developing human eye. *Endocrinology* **133**:600-7.
 76. **Masur, H., J. E. Kaplan, and K. K. Holmes.** 2002. Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. *Ann Intern Med* **137**:435-78.
 77. **Mertsch, K., I. Blasig, and T. Grune.** 2001. 4-Hydroxynonenal impairs the permeability of an in vitro rat blood-brain barrier. *Neurosci Lett* **314**:135-8.
 78. **Mischeck, U., J. Meyer, and H. J. Galla.** 1989. Characterization of gamma-glutamyl transpeptidase activity of cultured endothelial cells from porcine brain capillaries. *Cell Tissue Res* **256**:221-6.
 79. **Mizuguchi, H., Y. Hashioka, A. Fujii, N. Utoguchi, K. Kubo, S. Nakagawa, A. Baba, and T. Mayumi.** 1994. Glial extracellular matrix modulates gamma-glutamyl transpeptidase activity in cultured bovine brain capillary and bovine aortic endothelial cells. *Brain Res* **651**:155-9.
 80. **Morita, K., H. Sasaki, M. Furuse, and S. Tsukita.** 1999. Endothelial claudin: claudin-5/TM6CF constitutes tight junction strands in endothelial cells. *J Cell Biol* **147**:185-94.
 81. **Mosmann, T.** 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J Immunol Methods* **65**:55-63.
 82. **Muruganandam, A., L. M. Herx, R. Monette, J. P. Durkin, and D. B. Stanimirovic.** 1997. Development of immortalized human cerebromicrovascular endothelial cell line as an in vitro model of the human blood-brain barrier. *Faseb J* **11**:1187-97.
 83. **Nitta, T., M. Hata, S. Gotoh, Y. Seo, H. Sasaki, N. Hashimoto, M. Furuse, and S. Tsukita.** 2003. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. *J Cell Biol* **161**:653-60.
 84. **Nitz, T., T. Eisenblatter, K. Psathaki, and H. J. Galla.** 2003. Serum-derived factors weaken the barrier properties of cultured porcine brain capillary endothelial cells in vitro. *Brain Res* **981**:30-40.
 85. **Olivier, J. C., L. Fenart, R. Chauvet, C. Pariat, R. Cecchelli, and W. Couet.** 1999. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. *Pharm Res* **16**:1836-42.
 86. **Omidi, Y., L. Campbell, J. Barar, D. Connell, S. Akhtar, and M. Gumbleton.** 2003. Evaluation of the immortalised mouse brain capillary endothelial cell line, b.End3, as an in vitro blood-brain barrier model for drug uptake and transport studies. *Brain Res* **990**:95-112.

-
87. **Pardridge, W. M., J. Eisenberg, and T. Yamada.** 1985. Rapid sequestration and degradation of somatostatin analogues by isolated brain microvessels. *J Neurochem* **44**:1178-84.
 88. **Pfefferkorn, E. R., S. E. Borotz, and R. F. Nothnagel.** 1993. Mutants of *Toxoplasma gondii* resistant to atovaquone (566C80) or decoquinatate. *J Parasitol* **79**:559-64.
 89. **Porter, S. B., and M. A. Sande.** 1992. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. *N Engl J Med* **327**:1643-8.
 90. **Ramge, P., R. E. Unger, J. B. Oltrogge, D. Zenker, D. Begley, J. Kreuter, and H. Von Briesen.** 2000. Polysorbate-80 coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human and bovine primary brain capillary endothelial cells. *Eur J Neurosci* **12**:1931-40.
 91. **Raub, T. J., S. L. Kuentzel, and G. A. Sawada.** 1992. Permeability of bovine brain microvessel endothelial cells in vitro: barrier tightening by a factor released from astrogloma cells. *Exp Cell Res* **199**:330-40.
 92. **Reboli, A. C., and H. D. Mandler.** 1992. Encephalopathy and psychoses associated with sulfadiazine in two patients with AIDS and CNS toxoplasmosis. *Clin Infect Dis* **15**:556-7.
 93. **Reichel, T. F., R. M. Ramus, J. T. Caire, L. S. Hynan, K. P. Magee, and D. M. Twickler.** 2003. Fetal central nervous system biometry on MR imaging. *AJR Am J Roentgenol* **180**:1155-8.
 94. **Remington, J. S., and J. L. Vilde.** 1991. Clindamycin for toxoplasma encephalitis in AIDS. *Lancet* **338**:1142-3.
 95. **Rolan, P. E., A. J. Mercer, B. C. Weatherley, T. Holdich, H. Meire, R. W. Peck, G. Ridout, and J. Posner.** 1994. Examination of some factors responsible for a food-induced increase in absorption of atovaquone. *Br J Clin Pharmacol* **37**:13-20.
 96. **Romand, S., M. Pudney, and F. Derouin.** 1993. In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against *Toxoplasma gondii*. *Antimicrob Agents Chemother* **37**:2371-8.
 97. **Roux, F., O. Durieu-Trautmann, N. Chaverot, M. Claire, P. Mailly, J. M. Bourre, A. D. Strosberg, and P. O. Couraud.** 1994. Regulation of gamma-glutamyl transpeptidase and alkaline phosphatase activities in immortalized rat brain microvessel endothelial cells. *J Cell Physiol* **159**:101-13.
 98. **Roux, F. S., R. Mokni, C. C. Hughes, P. M. Clouet, J. M. Lefauconnier, and J. M. Bourre.** 1989. Lipid synthesis by rat brain microvessel endothelial cells in tissue culture. *J Neuropathol Exp Neurol* **48**:437-47.
 99. **Roux, K. J., S. A. Amici, and L. Notterpek.** 2004. The temporospatial expression of peripheral myelin protein 22 at the developing blood-nerve and blood-brain barriers. *J Comp Neurol* **474**:578-88.
 100. **Rubin, L. L.** 1992. Endothelial cells: adhesion and tight junctions. *Curr Opin Cell Biol* **4**:830-3.
 101. **Rubin, L. L., K. Barbu, F. Bard, C. Cannon, D. E. Hall, H. Horner, M. Janatpour, C. Liaw, K. Manning, J. Morales, and et al.** 1991. Differentiation of brain endothelial cells in cell culture. *Ann N Y Acad Sci* **633**:420-5.

-
102. **Scholer, N., K. Krause, O. Kayser, R. H. Muller, K. Borner, H. Hahn, and O. Liesenfeld.** 2001. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. *Antimicrob Agents Chemother* **45**:1771-9.
 103. **Schwarz, C., and W. Mehnert.** 1999. Solid lipid nanoparticles (SLN) for controlled drug delivery. II. Drug incorporation and physicochemical characterization. *J Microencapsul* **16**:205-13.
 104. **Sordet, F., Y. Aumjaud, H. Fessi, and F. Derouin.** 1998. Assessment of the activity of atovaquone-loaded nanocapsules in the treatment of acute and chronic murine toxoplasmosis. *Parasite* **5**:223-9.
 105. **Suzuki, Y., F. K. Conley, and J. S. Remington.** 1989. Importance of endogenous IFN-gamma for prevention of toxoplasmic encephalitis in mice. *J Immunol* **143**:2045-50.
 106. **Suzuki, Y., H. Kang, S. Parmley, S. Lim, and D. Park.** 2000. Induction of tumor necrosis factor-alpha and inducible nitric oxide synthase fails to prevent toxoplasmic encephalitis in the absence of interferon-gamma in genetically resistant BALB/c mice. *Microbes Infect* **2**:455-62.
 107. **Suzuki, Y., M. A. Orellana, S. Y. Wong, F. K. Conley, and J. S. Remington.** 1993. Susceptibility to chronic infection with *Toxoplasma gondii* does not correlate with susceptibility to acute infection in mice. *Infect Immun* **61**:2284-8.
 108. **Tilling, T., C. Engelbertz, S. Decker, D. Korte, S. Huwel, and H. J. Galla.** 2002. Expression and adhesive properties of basement membrane proteins in cerebral capillary endothelial cell cultures. *Cell Tissue Res* **310**:19-29.
 109. **Torres, R. A., W. Weinberg, J. Stansell, G. Leoung, J. Kovacs, M. Rogers, and J. Scott.** 1997. Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS. Atovaquone/Toxoplasmic Encephalitis Study Group. *Clin Infect Dis* **24**:422-9.
 110. **Unkmeir, A., K. Latsch, G. Dietrich, E. Wintermeyer, B. Schinke, S. Schwender, K. S. Kim, M. Eigenthaler, and M. Frosch.** 2002. Fibronectin mediates Opc-dependent internalization of *Neisseria meningitidis* in human brain microvascular endothelial cells. *Mol Microbiol* **46**:933-46.
 111. **Veronesi, B.** 1996. Characterization of the MDCK cell line for screening neurotoxicants. *Neurotoxicology* **17**:433-43.
 112. **Vorbrodt, A. W., and D. H. Dobrogowska.** 2003. Molecular anatomy of intercellular junctions in brain endothelial and epithelial barriers: electron microscopist's view. *Brain Res Brain Res Rev* **42**:221-42.
 113. **Weisgraber, K. H., T. L. Innerarity, K. J. Harder, R. W. Mahley, R. W. Milne, Y. L. Marcel, and J. T. Sparrow.** 1983. The receptor-binding domain of human apolipoprotein E. Monoclonal antibody inhibition of binding. *J Biol Chem* **258**:12348-54.
 114. **Williams, R. L., W. Risau, H. G. Zerwes, H. Drexler, A. Aguzzi, and E. F. Wagner.** 1989. Endothelioma cells expressing the polyoma middle T oncogene induce hemangiomas by host cell recruitment. *Cell* **57**:1053-63.
 115. **Williams, S. K., J. F. Gillis, M. A. Matthews, R. C. Wagner, and M. W. Bitensky.** 1980. Isolation and characterization of brain endothelial cells: morphology and enzyme activity. *J Neurochem* **35**:374-81.

-
116. **Wilson, E. H., and C. A. Hunter.** 2004. The role of astrocytes in the immunopathogenesis of toxoplasmic encephalitis. *Int J Parasitol* **34**:543-8.
 117. **Zlokovic, B. V., and M. L. Apuzzo.** 1998. Strategies to circumvent vascular barriers of the central nervous system. *Neurosurgery* **43**:877-8.